P1285 : Forecasting the disease burden of chronic hepatitis C in Russia

Chulanov, Vladimir; Sagalova, Olga; Блохина, Н. П.; Мамонова, Н. А.; Nurmukhametova, E.; Pimenov, Nikolay; Rakhmanova, Aza; Razavi, Homie; Razavi‐Shearer, Kathryn; Shevaldin, A.; Chesnokov, E. V.; Sokolov, Svyatoslav S.; Strebkova, E.A. Strebkova; Знойко, О О; Shestakova, I V

doi:10.1016/s0168-8278(15)31480-x

Cited by 4 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Кроме того, эта стратегия приведет к увеличению количества смертей вследствие заболеваний печени более чем на 20 тыс. [24].…”

Section: терапевтический архив 11 2015unclassified

“…Для повышения эффективности лечения предложено существенно увеличить частоту УВО в 2016 г. за счет использования высокоэффектив-*Распространенность генотипов ВГС в России: генотип 1а -2,1% генотип 1b -52,8%, генотип 2 -8,1%, генотип 3 -36,3%, генотипы 4-6 -0, другие генотипы -0,7%. [24]. С учетом того, что одним из ведущих путей передачи HCV является употребление инъекционных наркотиков, реализация такой стратегии должна включать комплекс мер, направленных на борьбу с незаконным распространением психотропных препаратов, снижение риска передачи инфекции среди потребителей наркотиков (программы снижения вреда) [25], а также более активное их включение в программу лечения [26].…”

unclassified

See 1 more Smart Citation

Chronic hepatitis C in Russia: current challenges and prospects

Chulanov¹,

Pimenov²,

Мамонова³

et al. 2015

Ter. arkh.

View full text Add to dashboard Cite

show abstract

Section: терапевтический архив 11 2015unclassified

unclassified

Chronic hepatitis C in Russia: current challenges and prospects

Chulanov¹,

Pimenov²,

Мамонова³

et al. 2015

Ter. arkh.

View full text Add to dashboard Cite

show abstract

“…Then the second-generation DAAD increased the probability of achieving the clinical endpoint -getting sustained virologic response (SVR) in 90-100 % of cases independently of treatment experience, cirrhosis, viral genotype and HIV co-infection [1]. Achieving SVR in 99 % of cases is deemed to complete recovery from HCV [9]. Besides, in the absence of cirrhosis at the onset of treatment achieving SVR makes it possible to normalize liver function, i. e. to stop the progression of the disease and prevent the development of life-threatening conditions (for example, hepatocellular carcinoma [HCC]) [9].…”

mentioning

confidence: 99%

Pharmacoeconomic analysis of sofosbuvir for the treatment of chronic hepatitis c (genotype 1) in the russian federation

Kulikov¹,

Babiy²

2017

Pharmacoeconom T&P

View full text Add to dashboard Cite

The objectives of this study were to determine the most advantageous antiviral therapy option for chronic hepatitis C (CHC) (peginterferon alfa + ribavirin (PegIFN + RBV) 48 weeks (F0-F4), peginterferon alfa + simeprevir + ribavirin (PegIFN + SMV + RBV) 24 weeks (F0-F4), peginterferon alfa + sofosbuvir + ribavirin (PegIFN + SOF + RBV) 12 weeks (F0-F4), dasabuvir + ombitasvir/paritaprevir/ritonavir (Dasabuvir + Ombitasvir/ paritaprevir/ritonavir) 12 weeks (F0-F3) and dasabuvir + ombitasvir/ paritaprevir/ritonavir + ribavirin (Dasabuvir + Ombitasvir/paritaprevir/ritonavir + RBV) 12 weeks (F4)) among treatment-naive and treatment-experienced patients (HCV genotype 1) based on the comparison of cost-effectiveness ratios and economic outcomes ("budget impact" analysis) from implementing the treatment strategy PegIFN-α + SOF + RBV instead of PegIFN-α + RBV, PegIFN-α + SIM + RBV and Dasabuvir + Ombitasvir/paritaprevir/ritonavir. Model-based pharmacoeconomic analysis has been conducted. The costeffectiveness analysis showed that independently of the former treatment experience of CHC (genotype 1) patients the combination PegIFN-α + SOF + RBV was a predominant regimen as compared to PegIFN-α + RBV and PegIFN-α + SMV + RBV. In the groups of patients without cirrhosis and with cirrhosis the highest QALY value was noted for Dasabuvir + Ombitasvir/ paritaprevir/ritonavir and Dasabuvir + Ombitasvir/paritaprevir/ritonavir + RBV combinations, respectively. Also a smaller cost-effectiveness ratio (CER) relative to the two above regimens was noted for PegIFN-α + SOF + RBV. In the group of treatment-naive patients without cirrhosis incremental costeffectiveness ratio (ICER) of Dasabuvir + Ombitasvir/paritaprevir/ritonavir vs PegIFN-α + SOF + RBV was higher than willingness-to-pay threshold (WPT), whereas in the group of patients with cirrhosis ICER Dasabuvir + Ombitasvir/paritaprevir/ritonavir

show abstract

“…The total number of HCV-infected patients living in the Russian Federation has been evaluated by experts as equal to 4-5 million people, while only 1.8 million HCV-infected patients were registered in 2012 [3].…”

mentioning

confidence: 99%

“…In the Russian Federation approximately 0.1% of estimated number of patients with chronic hepatitis C (about 5,500 people) get access to AVT every year. [3].…”

mentioning

confidence: 99%

Pharmacoeconomic analysis of combination of medicines daclatasvir and asunaprevir in treatment of chronic hepatitis C in the Russian Federation

Kulikov¹,

Babiy²,

Shestakova³

2016

Pharmacoeconom T&P

View full text Add to dashboard Cite

The goals of this study was: 1. to evaluate the superior regimen of antiviral drug treatment of chronic hepatitis C (daclatasvir + asunaprevir (a combination of the medicinal products) versus perginterferon alfa + ribavirin or peginterferon alfa + ribavirin + simeprevir or paritaprevir + ritonavir + ombitasvir + dasabuvir) in treatment-naive and treatment-experienced patients (HCV genotype 1b) without liver cirrhosis and with liver cirrhosis based on comparison of cost, effectiveness and safety; 2. To define, using «budget impact» analysis, economic outcomes of including daclatasvir + asunaprevir in current practice of HCV treatment This analysis was performed using two scenarios of the adjusted model "The MONARCH Cost-effectiveness Model". «Budget impact» analysis was conducted using adapted model «ALLY: Daklinza ® (Daclatasvir) Budget Impact Model». The study demonstrated that the first study hypothesis was correct: the combination of the medicinal products for treatment of HCV-infection (HCV genotype 1) daclatasvir + asunaprevir was found to have advantages over the combinations peginterferon alfa + ribavirin, peginterferon alfa + ribavirin + simeprevir and dasabuvir, ombitasvir + paritaprevir + ritonavir in respect of the cost-effectiveness ratio. Furthermore, results of «budget impact» analysis confirmed the second study hypothesis-introduction of DCV + ASV in current practice of HCV treatment will lead to decreasing of complication treatment costs.

show abstract

P1285 : Forecasting the disease burden of chronic hepatitis C in Russia

Cited by 4 publications

References 0 publications

Chronic hepatitis C in Russia: current challenges and prospects

Chronic hepatitis C in Russia: current challenges and prospects

Pharmacoeconomic analysis of sofosbuvir for the treatment of chronic hepatitis c (genotype 1) in the russian federation

Pharmacoeconomic analysis of combination of medicines daclatasvir and asunaprevir in treatment of chronic hepatitis C in the Russian Federation

Contact Info

Product

Resources

About